Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 61-67

  Jacobson, Jeffrey M ^a,l   Spritzler, John ^b   Fox, Lawrence ^d   Fahey, John L ^f   Jackson, J Brooks ^e   Chernoff, Miriam ^b   Wohl, David A ^h   Wu, Albert W ^e   Hooton, Thomas M ⁱ   Sha, Beverly E ^j   Shikuma, Cecilia M ^k   MacPhail, Laurie A ^g   Simpson, David M ^a   Trapnell, Carol B ^d   Basgoz, Nesli ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j RUSH MEDICAL COLLEGE   (United States)

^k UNIVERSITY OF HAWAII   (United States)

^l MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; THALIDOMIDE;

ADULT; APHTHOUS ULCER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS ULCER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SOMNOLENCE; TREATMENT OUTCOME; ULCER HEALING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIGENS, CD; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PLACEBOS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STOMATITIS, APHTHOUS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; ULCER; UNITED STATES;

EID: 0032977309     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314834     Document Type: Article

References (17)

1. Bach MC, Valenti AJ, Howell DA, Smith TJ. Odynophagia from aphthous ulcers of the pharynx and the esophagus in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;109:338-9.
2. Kotler DP, Reka S, Orenstein JM, Fox CH. Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome: characterization and treatment with corticosteroids. J Clin Gastroenterol 1992;15:284-90.
3. Wilcox CM, Schwartz DA, Clark WS. Causes, response to therapy, and long-term outcome of esophageal ulcer in patients with human immunodeficiency virus infection. Ann Intern Med 1995;123:143-9.
4. Wilcox CM, Schwartz DA. Comparison of two corticosteroid regimens for the treatment of idiopathic esophageal ulcerations associated with HIV infection. Am J Gastroenterol 1994;89:2163-7.
5. Ryan J, Colman J, Pedersen J. Thalidomide to treat esophageal ulcer in AIDS [letter]. N Engl J Med 1992;327:208-9.
6. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refactory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20:250-4.
7. Alexander LN, Wilcox CM. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Retroviruses 1997;13:301-4.
8. MacPhail LA, Greenspan D, Feigal DW, Lennetto ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection: description of ulcer types and analysis of T-lymphocyte subsets. Oral Surg Oral Med Oral Pathol 1991;71:678-83.
9. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
10. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991;29:786-98.
11. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
12. Breslow N, Day NE. Statistical methods in cancer research. Vol I. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980;128 (IARC scientific publications no. 32).
13. Agresti A. Categorical data analysis, New York; John Wiley and Sons, 1990: 60-6, 232.
14. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975;55-65, 123-32, 300.
15. Birnkrant D. Thalidomide for aphthous ulcers in HIV infection [letter]. N Engl J Med 1997;337:1086-7.
16. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type I. Proc Natl Acad Sci USA 1993;90:5974-8.
17. Shibata Y, Sasaki K, Hashimoto Y, Iwasaki S. Tumor necrosis factor-α production enhancers with a phenylphthalimide skeleton. Biochem Biophys Res Commun 1994;205:1992-7.